Canaccord Genuity Maintains Buy on HeartFlow, Raises Price Target to $56
Canaccord Genuity analyst William Plovanic maintains HeartFlow (NASDAQ:HTFL) with a Buy and raises the price target from $45 to $56.
Stocks · News reference
Morgan Stanley Maintains Equal-Weight on HeartFlow, Raises Price Target to $40
Morgan Stanley analyst Patrick Wood maintains HeartFlow (NASDAQ:HTFL) with a Equal-Weight and raises the price target from $35 to $40.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Software as a Medical Device Market Set for Rapid Growth Through 2034 as AI Innovation, Digital Health Adoption, and Regulatory Advances Reshape the Competitive Landscape
The global Software as a Medical Device (SaMD) market is projected to grow from USD 2.10 billion in 2025 to USD 8.90 billion by 2034, expanding at a CAGR of 17.4%. Growth is driven by AI-enabled diagnostics, digital therapeutics, cloud-based deployment, and maturing regulatory pathways. Diagnostic and screening software leads with 42% market share, while radiology applications dominate at 34%. North America holds 45% of the market, with Asia-Pacific expected to record the fastest growth.
UBS Initiates Coverage On HeartFlow with Neutral Rating, Announces Price Target of $55
Watching Heartflow; Hearing Investor Business Daily SwingTrader Buys Stock